Researchers have developed an innovative new nanopore sequencing assay to identify carriers of fragile X syndrome (FXS), the leading cause of monogenic autism spectrum disorder and inherited intellectual disabilities. The study, published in The Journal of Molecular Diagnostics, addresses the urgent need for a screening tool to identify carriers of FXS in a more comprehensive, faster, efficient, and cost-effective way compared to current methods, for better informed genetic counseling.
Novel assay promises more efficient screening for carriers of fragile X syndrome
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
